索拉非尼联合经皮肝动脉化疗栓塞术治疗原发性肝癌临床效果分析  

Clinical Effect Analysis of Sorafenib Combined with Transarterial Chemoembolization in Treatment of Primary Liver Cancer

作　　者：池希 张佳光[2] Chi Xi;Zhang Jia-guang(China Three Gorges University,Yichang 443000,Hubei Province,China;Third Clinical Medical College of China Three Gorges University,Yichang 443000,Hubei Province,China)

机构地区：[1]三峡大学,湖北宜昌443000 [2]三峡大学第三临床医学院,湖北宜昌443000

出　　处：《中国社区医师》2022年第22期16-18,共3页Chinese Community Doctors

摘　　要：目的:分析索拉非尼联合经皮肝动脉化疗栓塞术(TACE)治疗原发性肝癌(PLC)的临床疗效。方法:选取2020年9月-2022年1月三峡大学第三临床医学院治疗的原发性肝癌患者100例为观察对象,采用随机数字表法分成观察组和对照组,各50例,对照组采取TACE治疗,观察组在对照组的基础上加用索拉非尼靶向药物治疗,对比两组近期疗效、血清血管内皮生长因子(VEGF)水平、不良反应发生率等。结果:观察组疾病控制率优于对照组,差异有统计学意义(P<0.05);治疗后,观察组血管内皮生长因子(VEGF)水平低于对照组,差异有统计学意义(P<0.05);观察组皮疹、高血压、手足综合征、腹泻不良反应发生率高于对照组,差异有统计学意义(P<0.05)。结论:索拉非尼联合TACE治疗PLC疗效显著,可降低血管内皮生长因子,但不良反应发生率较高,可能是中晚期肝癌更理想的治疗手段。Objective:To analyze the clinical efficacy of sorafenib combined with transarterial chemoembolization(TACE)in the treatment of primary liver cancer.Methods:From September 2020 to January 2022,100 patients with primary liver cancer who were treated in the Third Clinical Medical College of China Three Gorges University were selected as the observation objects,and were divided into an observation group and a control group by random number table method,with 50 cases in each group.The control group was given TACE treatment,and the observation group was given sorafenib targeted drug treatment on the basis of the control group.The short-term efficacy,serum vascular endothelial growth factor(VEGF)level,and incidence of adverse reactions were compared between the two groups.Results:The disease control rate of the observation group was better than that of the control group,and the difference was statistically significant(P<0.05).After treatment,the level of VEGF in the observation group was lower than that in the control group,and the difference was statistically significant(P<0.05).The incidence of adverse reactions including skin rash,hypertension,hand-foot syndrome and diarrhea in the observation group was higher than that in the control group,and the difference was statistically significant(P<0.05).Conclusion:Sorafenib combined with TACE has significant curative effect in the treatment of primary liver cancer,and can reduce VEGF,but the incidence of adverse reactions is high,which may be a more ideal treatment for middle-stage and advanced liver cancer.

关 键 词：经皮肝动脉化疗栓塞术 索拉非尼 靶向药物 原发性肝癌 

分 类 号：R735.7[医药卫生—肿瘤]